Azilva Ranked No. 1 for Third Consecutive Month in Both GP, HP Markets in July: Rep Track Survey

According to Anterio Inc.’s Rep Track Survey, which investigates doctors’ recollections on drug detailing activities, Takeda Pharmaceutical’s novel angiotensin receptor blocker (ARB) Azilva (azilsartan) ranked first for the third consecutive month both in the GP market (99 beds or less)...read more